Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences

Data Will Highlight Potential Advantages of Rezafungin for the
Treatment and Prevention of Invasive Fungal Infections

SAN DIEGO–(BUSINESS WIRE)–Jun. 15, 2018–
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that Dr. Taylor Sandison, chief medical officer, will present
clinical efficacy and safety data for the company’s lead antifungal
rezafungin for the treatment and prevention of invasive fungal
infections at two upcoming, global infectious disease conferences.
Abstracts highlighting rezafungin data have been accepted at The 20th…

READ FULL TEXT

Leave a Reply

Your email address will not be published.